A homogeneous high-DAR antibody–drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides

• Published in: Chemical science (Cambridge) Vol. 13; no. 11; pp. 3147 - 3160
• Main Authors: Zacharias, Neelie, Podust, Vladimir N., Kajihara, Kimberly K., Leipold, Douglas, Del Rosario, Geoffrey, Thayer, Desiree, Dong, Emily, Paluch, Maciej, Fischer, David, Zheng, Kai, Lei, Corinna, He, Jintang, Ng, Carl, Su, Dian, Liu, Luna, Masih, Shabkhaiz, Sawyer, William, Tinianow, Jeff, Marik, Jan, Yip, Victor, Li, Guangmin, Chuh, Josefa, Morisaki, J. Hiroshi, Park, Summer, Zheng, Bing, Hernandez-Barry, Hilda, Loyet, Kelly M., Xu, Min, Kozak, Katherine R., Phillips, Gail Lewis, Shen, Ben-Quan, Wu, Cong, Xu, Keyang, Yu, Shang-Fan, Kamath, Amrita, Rowntree, Rebecca K., Reilly, Dorothea, Pillow, Thomas, Polson, Andrew, Schellenberger, Volker, Hazenbos, Wouter L. W., Sadowsky, Jack
• Format: Journal Article
• Language: English
• Published: England Royal Society of Chemistry 16.03.2022; The Royal Society of Chemistry
• Subjects: Antibodies; Antigens; Chemistry; Conjugates; Payloads; Polypeptides

The antibody–drug conjugate (ADC) is a well-validated modality for the cell-specific delivery of small molecules with impact expanding rapidly beyond their originally-intended purpose of treating cancer. However, antibody-mediated delivery (AMD) remains inefficient, limiting its applicability to tar...